Tirzepatide Pens Manufacturer - Dual GIP/GLP-1 Receptor Agonist

Tirzepatide pens represent a breakthrough in peptide-based therapies for metabolic disorders. As a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, tirzepatide offers superior efficacy in glucose control and weight management compared to single-action alternatives.

Our pharmaceutical-grade tirzepatide pens contain 99.9% pure peptide compound with the molecular formula C225H348N48O68. The white powder formulation maintains excellent stability when stored properly in cool, dry conditions. Each pen delivers precise dosing for research applications.

Clinical studies demonstrate tirzepatide's remarkable weight loss potential, with trial participants achieving 15-20.9% body weight reduction over 72 weeks. The compound's unique mechanism combines the benefits of both GIP and GLP-1 receptor activation in a single molecule, creating synergistic metabolic effects.

For research institutions and pharmaceutical developers, our tirzepatide pens offer:

• Consistent high purity (99.9%)
• Precise dosing formulations
• Stable shelf life
• Custom packaging options
• Bulk order availability

The PEG-modified lysine side chain in tirzepatide's structure enhances water solubility while maintaining biological activity. This modification contributes to the compound's extended half-life and sustained receptor activation profile.

Note: This product is intended for research purposes only. Not for human consumption or personal use.